Well-known industry leader is returning to Big Pharma to take on the Country President role from next year

Australian superstars are being snapped up by pharma to educate the public with J&J the latest to partner with a big name

These companies have racked up billions of dollars in corporate fines, penalties and settlements

Fast-growing organisation in a booming but controversial space appoints its first CEO with an internal promotion

Latest figures from Amgen's Australian Patient Access Gap Tracker reveals patients are waiting longer than ever

Mid-year estimates reveal how much the Federal Govt expects new listings to add to the total cost of the PBS over four years

Company braces for a US$17 billion loss of exclusivity hit and is counting on a burgeoning pipeline to turn its fortunes around

Locals are making their mark in the US, with the FDA handing out designations for up-and-coming Aussie treatments

Nominations open for these prestigious Australian Awards, showcasing outstanding contributions to industry

Another stride forward toward commercialisation for this Aussie product which has the potential to revolutionise vaccine delivery

With 2026 shaping up as a make-or-break year for Australian pharma, the country's industry leaders have high hopes

Big Pharma joins its second industry association this year, becoming a Class One member of Medicines Australia

First subcutaneous PD-1 inhibitor has been approved in Australia, offering more convenient treatment options for patients

Lilly unveils another winner with its triple agonist relatrutide on track to become the most effective weight loss treatment on the market

There's no doubt it's time for a break and ANZ Country Leaders have revealed what they'll be doing over Summer to rest and reset

Senior leaders from government, industry and patient advocacy will meet next February to end the era of medicines shortages

New form of an old drug registered on the ARTG could completely change the way people use it, and it's already on PBAC's agenda

HCPs are becoming more dissatisfied with the service provided by pharmas, but some companies are bucking the trend